Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07795268 177Lu-NY108 Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795268 clinical trial report covering 177Lu-NY108, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07795346 ATG-022 CLDN18.2 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07795346 clinical trial report covering ATG-022, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794397 Poterepatide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794397 clinical trial report covering Poterepatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794761 Berobenatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794761 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794748 Multivalent Pneumococcal Conjugate Vaccine(Pfizer) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794748 clinical trial report covering Multivalent Pneumococcal Conjugate Vaccine(Pfizer), Phase 3, endpoints, sponsor, geography, readout timing and d
Latest Hotspot
8 min read
ChiCTR2600131273 TARLATAMAB-DLLE Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600131273 clinical trial report covering TARLATAMAB-DLLE, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07794774 Berobenatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07794774 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07796100 Zocilurtatug Pelitecan Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07796100 clinical trial report covering Zocilurtatug Pelitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
Small Cell Lung Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
1 September 2026
2026 Small Cell Lung Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
9 min read
Kissei Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Kissei Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ration
Latest Hotspot
9 min read
JCR Pharmaceuticals Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for JCR Pharmaceuticals Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rational
Latest Hotspot
9 min read
ImmunityBio, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for ImmunityBio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.